Literature DB >> 19237173

Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy.

Hiroshi Hirata1, Yuji Hinoda, Nobuyuki Kikuno, Yutaka Suehiro, Varahram Shahryari, Ardalan E Ahmad, Z Laura Tabatabai, Mikio Igawa, Rajvir Dahiya.   

Abstract

PURPOSE: Approximately 10% to 26% of patients show biochemical failure after radical prostatectomy or radiation therapy. The importance of cell cycle and apoptosis pathways in prostate cancer has been reported. However, to our knowledge there is currently no information on the role of apoptosis and cell cycle related gene polymorphisms in prostate cancer cases. We investigated several polymorphisms related to the cell cycle and apoptosis, and their role in biochemical failure after radical prostatectomy.
MATERIALS AND METHODS: We genotyped 6 single nucleotide polymorphisms in 6 genes, including p53 (rs1042522), p21 (rs1801270), MDM2 (rs2279744), PTEN (rs701848), GNAS1 (rs7121) and bcl2 (rs2279115), using polymerase chain reaction-restriction fragment length polymorphism and direct DNA sequencing in 140 patients with prostate cancer and 167 age matched controls. The association of polymorphic variants with prostate specific antigen failure in patients with prostate cancer was analyzed by Kaplan-Meier curves.
RESULTS: A significant increase in the frequency of the C/C genotype of GNAS1 rs7121 was observed in patients compared with controls. Interestingly we found a significant difference in biochemical recurrence-free time between the bcl2 C/C and C/A+A/A genotypes. It was also noted that the bcl2 C/C genotype was an independent risk factor for biochemical recurrence after radical prostatectomy on multivariate analysis. There was no statistical difference in the genotype distributions of the other genes between patients and controls.
CONCLUSIONS: To our knowledge this is the first report documenting that bcl2 promoter region -938 C/C genotype carriers more frequently show biochemical recurrence than -938C/A+A/A carriers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19237173     DOI: 10.1016/j.juro.2008.11.093

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  24 in total

1.  Evaluation of single nucleotide polymorphisms (SNPs) in the p53 binding protein 1 (TP53BP1) gene in breast cancer patients treated with breast-conserving surgery and whole-breast irradiation (BCS + RT).

Authors:  Bruce G Haffty; Sharad Goyal; Diptee Kulkarni; Camille Green; Alexi Vazquez; Devora Schiff; Meena S Moran; Qifeng Yang; Shridar Ganesan; Kim M Hirsfield
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-18       Impact factor: 7.038

2.  The -938A/A genotype of BCL2 gene is associated with esophageal cancer.

Authors:  Zhigang Liu; Ruifang Sun; Weidong Lü; Chengxue Dang; Yangrong Song; Cheng Wang; Xi Zhang; Le Han; Hao Cheng; Wei Gao; Jia Liu; Guangyan Lei
Journal:  Med Oncol       Date:  2011-12-21       Impact factor: 3.064

3.  Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.

Authors:  Tong Sun; Gwo-Shu Mary Lee; William K Oh; Mark Pomerantz; Ming Yang; Wanling Xie; Matthew L Freedman; Philip W Kantoff
Journal:  Clin Cancer Res       Date:  2010-09-20       Impact factor: 12.531

Review 4.  Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis.

Authors:  Mohammad Haroon Khan; Aftab Khalil; Hamid Rashid
Journal:  Genet Res (Camb)       Date:  2015-04-17       Impact factor: 1.588

5.  Association of BCL2-938C>A genetic polymorphism with glioma risk in Chinese Han population.

Authors:  Wei Li; Chunfa Qian; Linxiong Wang; Hong Teng; Li Zhang
Journal:  Tumour Biol       Date:  2013-11-28

6.  The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysis.

Authors:  Jie Yang; Wen Gao; Ning-Hong Song; Wei Wang; Jie-Xiu Zhang; Pei Lu; Li-Xin Hua; Min Gu
Journal:  Asian J Androl       Date:  2012-08-20       Impact factor: 3.285

Review 7.  The genetic epidemiology of prostate cancer and its clinical implications.

Authors:  Rosalind Eeles; Chee Goh; Elena Castro; Elizabeth Bancroft; Michelle Guy; Ali Amin Al Olama; Douglas Easton; Zsofia Kote-Jarai
Journal:  Nat Rev Urol       Date:  2013-12-03       Impact factor: 14.432

8.  Association between p53 Pro72Arg polymorphism and prostate cancer risk: a meta-analysis.

Authors:  Lifeng Zhang; Ning Shao; Qianqian Yu; Lixin Hua; Yuanyuan Mi; Ninghan Feng
Journal:  J Biomed Res       Date:  2011-01

Review 9.  The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.

Authors:  Naveen Kachroo; Vincent J Gnanapragasam
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-28       Impact factor: 4.553

10.  Association of genetic markers in the BCL-2 family of apoptosis-related genes with endometrial cancer risk in a Chinese population.

Authors:  Tsogzolmaa Dorjgochoo; Yong-Bing Xiang; Jirong Long; Jiajun Shi; Sandra Deming; Wang-Hong Xu; Hui Cai; Jiarong Cheng; Qiuyin Cai; Wei Zheng; Xiao-Ou Shu
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.